Good news for SENZ, LIFE, and PROT

crwefinancelogo2

signup3m

Sport Endurance, Inc (OTC:SENZ), a health supplement company, announced today that the Company management expects to generate over $7.4 million in sales of its revolutionary Liquid Gel Cap products through 2011. Management believes these figures will surpass $38.7 million in revenues by 2013.

Revenues will be derived from sale of the Company's breakthrough dietary supplements, including; 8 Hour Energy Liquid Gel Caps, Creatine Liquid Gel Caps, Natural Sleep Aid Liquid Gel Caps.

We are confident that we will meet or exceed these sales projections, said Robert Timothy, CEO of Sport Endurance, Inc. Our supplements for building muscle mass, providing 8 hour energy supplements, and sleep aids have been reduced to a tiny gel cap size, represent a revolution in dietary supplements. Our Company is among the first in the exciting Liquid Gel Cap field.

Taking into consideration the unique superiority of our products, the explosive growth of the energy supplement, and energy shot market, and our distribution partnerships and sales force, we believe that these estimates are actually quite conservative.

The market for energy-boosting products has ballooned by more than 400% over the past five years. Sales have grown from $1.2 billion in 2002 to an estimated $6.6 billion in 2007. Market research firm, Packaged Facts, also projects that the energy supplement market will reach $9.3 billion by 2011.

SENZ develops, manufactures, markets, and distributes, quality dietary supplements products throughout the United States. SENZ believes that improved health contributes to, and promotes a higher quality of life. It is SENZs goal to improve health by providing quality and effective nutritional supplements with their state of the art liquid gel cap delivery system. All Sport Endurance brand products are manufactured within the USA in FDA inspected facilities. SENZ primary focus is on three areas of health that most directly impact the lives of most Americans; energy/weight loss, muscle growth and maintenance, and sleep aid/relaxation.

Life Technologies Corporation (NASDAQ:LIFE) and the University of California at San Diego Moores Cancer Center recntly reported a partnership to use SOLID 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia (CLL), a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

CLL is one of four main types of leukemia, which primarily affects adults averaging 70 years old, and causes a slow increase in the number of white blood cells called B cells in the bone marrow. The cancerous cells spread from the marrow to the blood, and can also affect the lymph nodes and other organs, such as the liver and spleen. CLL eventually causes the bone marrow to fail and weakens the immune system.

LIFE is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics.

Proteonomix Inc (OTC:PROT) a company, which focuses on stem cell therapies for diabetes and cardiac injury, is planning to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells, which will serve as a catalyst for bringing feasible treatments to market. Working with top scientists and institutions around the world, Proteonomix is also working on dramatically increasing the donor-recipient match rate by establishing a cord blood bank that uses proprietary technology. Umbilical cord blood stem cells are already recognized as a viable therapy for more than 80 diseases, a number that continues to grow.

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has received ten thousand dollars from a third party (Stienhoff Limited) for two days of advertising for Sport Endurance, Inc. (OTCBB: SENZ) (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)